Univariate and multivariate Cox proportional hazards model for PFS and OS
| PFS . | Univariate . | P value . | Multivariate . | P value . |
|---|---|---|---|---|
| HR (95% CI) . | HR (95% CI) . | |||
| High-risk aberration status | 2.57 (1.63-4.06) | 4.6E−5 | 4.10 (2.24-7.52) | 4.9E−6 |
| Age | 1.03 (1.01-1.06) | .016 | 1.03 (0.99-1.07) | .15 |
| KPS | 0.99 (0.96-1.02) | .48 | 0.99 (0.95-1.02) | .49 |
| IELSG risk group | 1.62 (0.82-3.23) | .17 | 2.37 (0.92-6.14) | .07 |
| MSKCC score | 1.71 (1.02-2.86) | .041 | 0.55 (0.23-1.3) | .17 |
| IOL disease | 1.61 (0.62-4.19) | .33 | 1.83 (0.63-5.34) | .27 |
| Consolidation | 0.11 (0.05-0.25) | 1.5E−7 | 0.03 (0.01-0.10) | 2.6E−10 |
| Maintenance | 0.96 (0.34-2.73) | .94 | 0.05 (0.01-0.21) | 4.3E−5 |
| OS | Univariate | P value | Multivariate | P value |
| HR (95% CI) | HR (95% CI) | |||
| High-risk aberration status | 2.46 (1.13-5.38) | .024 | 2.03 (0.86-4.79) | .10 |
| Age | 1.04 (1-1.09) | .049 | 1.02 (0.95-1.08) | .61 |
| KPS | 0.97 (0.94-1.01) | .18 | 0.93 (0.85-1.02) | .13 |
| IELSG risk group | 5.01 (1.36-18.42) | .015 | 3.55 (0.77-16.37) | .10 |
| MSKCC score | 1.96 (0.9-4.29) | .091 | 0.40 (0.08-2.01) | .27 |
| IOL disease | 1.16 (0.31-4.35) | .83 | 0.44 (0.07-2.9) | .39 |
| Consolidation | 0.06 (0.01-0.43) | .0055 | 0.04 (0-0.44) | .008 |
| Maintenance | 2.45 (0.66-9.08) | .18 | 0.83 (0.19-3.72) | .81 |
| PFS . | Univariate . | P value . | Multivariate . | P value . |
|---|---|---|---|---|
| HR (95% CI) . | HR (95% CI) . | |||
| High-risk aberration status | 2.57 (1.63-4.06) | 4.6E−5 | 4.10 (2.24-7.52) | 4.9E−6 |
| Age | 1.03 (1.01-1.06) | .016 | 1.03 (0.99-1.07) | .15 |
| KPS | 0.99 (0.96-1.02) | .48 | 0.99 (0.95-1.02) | .49 |
| IELSG risk group | 1.62 (0.82-3.23) | .17 | 2.37 (0.92-6.14) | .07 |
| MSKCC score | 1.71 (1.02-2.86) | .041 | 0.55 (0.23-1.3) | .17 |
| IOL disease | 1.61 (0.62-4.19) | .33 | 1.83 (0.63-5.34) | .27 |
| Consolidation | 0.11 (0.05-0.25) | 1.5E−7 | 0.03 (0.01-0.10) | 2.6E−10 |
| Maintenance | 0.96 (0.34-2.73) | .94 | 0.05 (0.01-0.21) | 4.3E−5 |
| OS | Univariate | P value | Multivariate | P value |
| HR (95% CI) | HR (95% CI) | |||
| High-risk aberration status | 2.46 (1.13-5.38) | .024 | 2.03 (0.86-4.79) | .10 |
| Age | 1.04 (1-1.09) | .049 | 1.02 (0.95-1.08) | .61 |
| KPS | 0.97 (0.94-1.01) | .18 | 0.93 (0.85-1.02) | .13 |
| IELSG risk group | 5.01 (1.36-18.42) | .015 | 3.55 (0.77-16.37) | .10 |
| MSKCC score | 1.96 (0.9-4.29) | .091 | 0.40 (0.08-2.01) | .27 |
| IOL disease | 1.16 (0.31-4.35) | .83 | 0.44 (0.07-2.9) | .39 |
| Consolidation | 0.06 (0.01-0.43) | .0055 | 0.04 (0-0.44) | .008 |
| Maintenance | 2.45 (0.66-9.08) | .18 | 0.83 (0.19-3.72) | .81 |
Multivariate Cox proportional hazard analysis evaluated the high-risk aberration status, age, KPS, IELSG risk group, MSKCC score, IOL disease, receipt of consolidation and maintenance, and demonstrated a 4.10-fold increased risk of progression (P = 4.9E−6) and a 2.03-fold increased risk of death with the high-risk aberration status at the 4 loci (6p CN-LOH/6p21.3 HD, or mutations in BTG1, ETV6, or TP53). High-risk aberration status, KPS, IELSG risk group, MSKCC score, IOL, consolidation, and maintenance were treated as discrete variables, whereas age was treated as a continuous variable, with values provided in supplemental Table 2 and described in “Statistical analysis” of the supplemental Data. There were also no differences in the incidence or severity of treatment-related toxicities during induction between cohorts of patients that proceeded to consolidation, maintenance, or no additional therapy.
CI, confidence interval; IOL, intraocular lymphoma; MSKCC, Memorial Sloan Kettering Cancer Center.